Cargando…

Efficacy and Safety of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and High Thromboembolic Risk. A Systematic Review

Background: The aim of the study was to evaluate the efficacy and safety of direct oral anticoagulants (DOACs) in a subgroup of patients with atrial fibrillation (AF), CHADS(2) score ≥3, advanced age, and heart failure (HF) coming from the main DOACs randomized clinical trials. Methods: We searched...

Descripción completa

Detalles Bibliográficos
Autores principales:	Acanfora, Domenico, Ciccone, Marco Matteo, Scicchitano, Pietro, Ricci, Giovanni, Acanfora, Chiara, Uguccioni, Massimo, Casucci, Gerardo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6761253/ https://www.ncbi.nlm.nih.gov/pubmed/31607911 http://dx.doi.org/10.3389/fphar.2019.01048

Ejemplares similares

A Systematic Review of the Efficacy and Safety of Direct Oral Anticoagulants in Atrial Fibrillation Patients with Diabetes Using a Risk Index
por: Acanfora, Domenico, et al.
Publicado: (2021)

The Cross-Talk between Thrombosis and Inflammatory Storm in Acute and Long-COVID-19: Therapeutic Targets and Clinical Cases
por: Acanfora, Domenico, et al.
Publicado: (2021)

Relative lymphocyte count as an indicator of 3-year mortality in elderly people with severe COPD
por: Acanfora, Domenico, et al.
Publicado: (2018)

DIC-Like Syndrome Following Administration of ChAdOx1 nCov-19 Vaccination
por: Casucci, Gerardo, et al.
Publicado: (2021)

The Cross-Talk between Age, Hypertension and Inflammation in COVID-19 Patients: Therapeutic Targets
por: Casucci, Gerardo, et al.
Publicado: (2020)

Impaired Vagal Activity in Long-COVID-19 Patients
por: Acanfora, Domenico, et al.
Publicado: (2022)

Medium-term and long-term renal function changes with direct oral anticoagulants in elderly patients with atrial fibrillation
por: Armentaro, Giuseppe, et al.
Publicado: (2023)

Real-World Prevalence of Direct Oral Anticoagulant Off-Label Doses in Atrial Fibrillation: An Epidemiological Meta-Analysis
por: Shen, Nan-Nan, et al.
Publicado: (2021)

Is percutaneous coronary intervention safe during uninterrupted direct oral anticoagulant therapy in patients with atrial fibrillation and acute coronary syndromes?
por: De Luca, Leonardo, et al.
Publicado: (2021)

Comparative Effectiveness and Safety of Low-Dose Oral Anticoagulants in Patients With Atrial Fibrillation
por: Perreault, Sylvie, et al.
Publicado: (2022)

Eight pharmacokinetic genetic variants are not associated with the risk of bleeding from direct oral anticoagulants in non-valvular atrial fibrillation patients
por: Campos-Staffico, Alessandra M., et al.
Publicado: (2022)

Direct Oral Anticoagulants for Cancer-Associated Venous Thromboembolism
por: Masini, Marta, et al.
Publicado: (2023)

Direct oral anticoagulants and venous thromboembolism
por: Franchini, Massimo, et al.
Publicado: (2016)

Ten-Year Trends in the Use of Oral Anticoagulants in Australian General Practice Patients With Atrial Fibrillation
por: Bezabhe, Woldesellassie M., et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Venous Thromboembolism in China
por: Sun, Ke-Xin, et al.
Publicado: (2021)

Adherence to Direct Oral Anticoagulants in Patients With Non-Valvular Atrial Fibrillation: A Cross-National Comparison in Six European Countries (2008–2015)
por: Sabaté, M., et al.
Publicado: (2021)

Gender Differences in Atrial Fibrillation: From the Thromboembolic Risk to the Anticoagulant Treatment Response
por: Rago, Anna, et al.
Publicado: (2023)

Effectiveness and Safety of Oral Anticoagulants in Older Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis
por: Grymonprez, Maxim, et al.
Publicado: (2020)

Tailored Anticoagulation for Thromboembolic Risk Reduction in Paroxysmal Atrial Fibrillation
por: Matos, Jason D., et al.
Publicado: (2018)

Tailored Direct Oral Anticoagulation in Patients with Atrial Fibrillation: The Future of Oral Anticoagulation?
por: Samoš, Matej, et al.
Publicado: (2022)

Oral Anticoagulants Initiation in Patients with Atrial Fibrillation: Real-World Data from a Population-Based Cohort
por: Rodríguez-Bernal, Clara L., et al.
Publicado: (2017)

Major Bleeding Risk in Atrial Fibrillation Patients Co-Medicated With Non-Vitamin K Oral Anticoagulants and Antipsychotics
por: Chen, Chiung-Mei, et al.
Publicado: (2022)

ANMCO position paper ‘Appropriateness of prescribing direct oral anticoagulants in stroke and systemic thromboembolism prevention in adult patients with non-valvular atrial fibrillation’
por: Mocini, David, et al.
Publicado: (2022)

Thromboembolic and Bleeding Risk in Atrial Fibrillation Patients with Chronic Kidney Disease: Role of Anticoagulation Therapy
por: Magnocavallo, Michele, et al.
Publicado: (2020)

Efficacy and Safety of Direct Oral Anticoagulants Compared to Warfarin in Prevention of Thromboembolic Events Among Elderly Patients with Atrial Fibrillation
por: Kailas, Shilpa D, et al.
Publicado: (2016)

Risk and Management of Bleeding Complications with Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Venous Thromboembolism: a Narrative Review
por: Ballestri, Stefano, et al.
Publicado: (2022)

A Multilevel Analysis of Real-World Variations in Oral Anticoagulation Initiation for Atrial Fibrillation in Valencia, a European Region
por: García-Sempere, Aníbal, et al.
Publicado: (2017)

Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and cancer a meta-analysis
por: Mariani, Marco Valerio, et al.
Publicado: (2020)

Type 2 Diabetes, Atrial Fibrillation, and Direct Oral Anticoagulation
por: Prídavková, Dana, et al.
Publicado: (2019)

Direct Oral Anticoagulants in Patients With Cancer and Nonvalvular Atrial Fibrillation
por: Davis, Margot K., et al.
Publicado: (2021)

Effectiveness and Safety of Under or Over-dosing of Direct Oral Anticoagulants in Atrial Fibrillation: A Systematic Review and Meta-analysis of 148909 Patients From 10 Real-World Studies
por: Shen, Nan-Nan, et al.
Publicado: (2021)

Vitamin-K-antagonist phenprocoumon versus direct oral anticoagulants in patients with atrial fibrillation: a real-world analysis of German claims data
por: Warkentin, Lisette, et al.
Publicado: (2023)

Effectiveness and safety of oral anticoagulants for non-valvular atrial fibrillation: a population-based cohort study in primary healthcare in Catalonia
por: Giner-Soriano, Maria, et al.
Publicado: (2023)

Direct Oral Anticoagulants in Old and Frail Patients with Atrial Fibrillation: The Advantages of an Anticoagulation Service
por: Vedovati, Maria Cristina, et al.
Publicado: (2022)

Prevalence and clinical predictors of inappropriate direct oral anticoagulant dosage in octagenarians with atrial fibrillation
por: Carbone, Andreina, et al.
Publicado: (2022)

Thromboembolic Events in Patients with Hypertrophic Cardiomyopathy and Atrial Fibrillation During New Oral Anticoagulant Therapy
por: An, Myeonghyun, et al.
Publicado: (2023)

Efficacy and safety of anticoagulation in atrial fibrillation patients with intracranial hemorrhage: A systematic review and meta-analysis
por: Zhou, Qiang, et al.
Publicado: (2023)

Management of Direct Oral Anticoagulants in Patients with Atrial Fibrillation Undergoing Cardioversion
por: Coppola, Giuseppe, et al.
Publicado: (2019)

Convenience and satisfaction in direct oral anticoagulant–treated patients with atrial fibrillation
por: Piersma‐Wichers, Margriet, et al.
Publicado: (2021)

Comparison of phenprocoumon with direct oral anticoagulants in catheter ablation of atrial fibrillation
por: Gjermeni, Diona, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_d3nsvdgbt3ptf03k33jm3fdg86